Clinical Trial Update: A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD [Phase 2]

View source ↗

Summary

Phase 2 trial of GM-1020 for major depressive disorder has completed. The study evaluated single and multiple oral doses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• GM-1020

Snippet

Sponsor: Gilgamesh Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED